Year All202420232022202120202019 Jun 05, 2024 Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 May 22, 2024 Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024 May 21, 2024 Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH May 07, 2024 Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results Apr 30, 2024 Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024 Apr 25, 2024 Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study Apr 25, 2024 Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD Apr 09, 2024 Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024 Apr 03, 2024 Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects Mar 27, 2024 Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
May 21, 2024 Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
May 07, 2024 Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
Apr 25, 2024 Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
Apr 03, 2024 Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Mar 27, 2024 Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
